Fundz

Public Ventures Llc Completes First Public Company Financing As A Broker-Dealer For Cue Biopharma, Inc. (Nasdaq:Cue)

PUBLIC · CUENov 17, 2022

Round Type

Funding Round

BostonBiotechnologyHealth CareTherapeutics

Description

DALLAS, TX / November 17, 2022 / Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. (NASDAQ:CUE).

Quick answer

Cue Biopharma raised an undisclosed amount in a Funding Round round, dated November 17, 2022. Cue Biopharma is based in Boston, Massachusetts, United States.

How much did Cue Biopharma raise?
Cue Biopharma raised an undisclosed amount in a Funding Round round on November 17, 2022.
What does Cue Biopharma do?
Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease.
Where is Cue Biopharma based and how big is it?
Cue Biopharma is based in Boston, Massachusetts, United States. Fundz records about 29 employees.
Who are the decision-makers at Cue Biopharma?
Fundz holds 2 contacts at Cue Biopharma, including the Biotech CEO | Board Member & Chairman| LifeScience Advisor. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Cue Biopharma that raised within 45 days of this round, from Fundz verified event records.

  • GenSight Biologics raised $13M (Convertible Note) on December 23, 2022.
  • Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
  • QurAlis raised $60M on December 20, 2022.
  • Gallant raised $25M on December 15, 2022.
  • Alpha-9 Theranostics raised $75M (Series B) on December 14, 2022.
  • STORM Therapeutics raised $30M (Series B) on December 14, 2022.

Who to call at Cue Biopharma, and when

A new round usually means Cue Biopharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Cue Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cue Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cue Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cue Biopharma

Location

Boston, Massachusetts, United States

About

Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic biologics to selectively engage and modulate disease-relevant T cells for the treatment of autoimmune disease. Cue Biopharma’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T Cells) and biologics are designed to harness the curative potential of the body’s innate immune system through the selective modulation of disease-relevant T cells without the adverse effects of broad systemic immune activation.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cue Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsUsman A., Biotech CEO | Board Member & Chairman|… hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Cue Biopharma's next move

See what Strategic adds

Cue Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.